|Bid||59.05 x 1000|
|Ask||59.13 x 1100|
|Day's Range||58.40 - 59.36|
|52 Week Range||34.75 - 86.75|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.70|
Nevro Corp NYSE:NVROView full report here! Summary * Bearish sentiment is moderate Bearish sentimentShort interest | NeutralShort interest is moderate for NVRO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold NVRO had net inflows of $1.81 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
REDWOOD CITY, Calif. , May 20, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today ...
Nevro stock tumbled Friday after the medical technology company's spinal cord stimulator sales lagged the Street's expectations. Now, an analyst says the entire market could be challenged.
Nevro (NVRO) delivered earnings and revenue surprises of -119.70% and -6.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had a loss of $1.45. The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...
REDWOOD CITY, Calif. , May 9, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we will run through one way of estimating the intrinsic value of Nevro Corp. (NYSE:NVRO) b...
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif. , April 30, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...
Company to Host Conference Call on Thursday, May 9, 2019 at 1:30 p.m. PT / 4:30 p.m. ET REDWOOD CITY, Calif. , April 23, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that ...
They're the forerunners of Facebook and the original PayPal mafia. Find out the earnings for the top executives under 40 at Bay Area companies.
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Nevro Corp. (NVRO) is among a host of public and private companies marketing or developing medical devices to treat pain. Warning! GuruFocus has detected 2 Warning Signs with NVRO. Medical device companies that can help reduce opioid use promise to be rewarded handsomely and merit the attention of savvy investors.
Nevro Corp (NYSE: NVRO ) announced a series of board changes and the appointment of a new CEO after the close Tuesday. The medical device company's stock was surging Wednesday on the news. The changes ...
Check out the companies making headlines midday Wednesday:FedEx FDX — Shares of FedEx dropped 5.14 percent after the company reported lower-than-expected third-quarter earnings and reduced its earnings outlook for fiscal year 2019.